Wegovy or Zepbound: Choosing Your Path to Sustainable Weight Loss

Last reviewed: June 23, 2026

Last updated: June 23, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.

Both tirzepatide and semaglutide are FDA-approved glucagon-like peptide-1 (GLP-1) medications that help people lose weight by slowing digestion and reducing hunger signals. The key difference lies in their mechanisms: tirzepatide also activates the glucose-dependent insulinotropic polypeptide (GIP) receptor, making it a dual-action compound. Clinical trials show tirzepatide produces greater weight loss than semaglutide alone, with some patients losing 20–22% of body weight over 72 weeks.

How Tirzepatide and Semaglutide Work Differently

Semaglutide activates only the GLP-1 receptor, which slows stomach emptying, decreases appetite, and improves blood sugar control. This single-pathway approach works well for many people, especially those whose weight gain is driven by excessive hunger or emotional eating. Semaglutide has been studied for over a decade, and healthcare providers have extensive experience managing its side effects and dose adjustments.

Tirzepatide activates both GLP-1 and GIP receptors simultaneously. This dual-action mechanism engages two separate appetite-control pathways in your brain and pancreas. Research suggests that activating both pathways produces stronger appetite suppression and metabolic improvements than GLP-1 activation alone. In head-to-head trials, tirzepatide patients lost an average of 2–3 pounds more per month than semaglutide users at equivalent doses.

Clinical Evidence: Weight Loss Outcomes and Metabolic Benefits

The SURPASS trial family demonstrated tirzepatide's superior efficacy: participants taking the highest dose lost up to 22.5% of baseline body weight over 72 weeks, compared to 14.9% for the highest semaglutide dose in parallel studies. Tirzepatide also showed greater improvements in fasting blood sugar, cholesterol, and blood pressure—markers linked to long-term heart health. These outcomes suggest tirzepatide may offer broader metabolic benefit, particularly for people with prediabetes or metabolic syndrome alongside obesity.

Semaglutide remains highly effective for sustainable weight loss, with consistent 15–18% reductions in clinical trials and real-world data spanning longer follow-up periods. Some patients experience weight loss plateaus after 6–12 months on semaglutide, while others maintain steady progress. The choice between the two depends on your starting weight, metabolic risk factors, and how your body responds to single versus dual GLP-1/GIP activation.

Genetic Factors That Influence Your Medication Response

The PlexusDx Precision Peptide Genetic Test analyzes GIPR, FTO, and MC4R — variants that relate to GLP-1 and related signaling pathways. It does not predict your response to tirzepatide or determine your dose; it offers pathway-level context for a conversation with your provider. Genetics is a guide, not a guarantee.

PlexusDx offers the Precision Peptide Genetic Test, which analyzes 14 peptide pathways and maps 150+ genetic insights including GIPR rs1800437, FTO rs9939609, and MC4R rs17782313. This test reveals whether your genetics favor GLP-1 monotherapy or the dual GLP-1/GIP approach of tirzepatide. Understanding your peptide-pathway genetics helps you start with the right medication and avoid trial-and-error treatment.

Cost, Access, and Personalized Dosing at PlexusDx

PlexusDx offers compounded tirzepatide injections at $289/mo month-to-month, or from $249/mo on the 6-month plan from licensed 503A compounding pharmacies, with no insurance required and no membership fees. Semaglutide injections begin at $189/mo (or $149/mo on the 6-month plan). Both medications are available across all 50 states and qualify for HSA and FSA funding. Your dose may need to go up as your body adapts, but your price won't—PlexusDx uses a flat monthly rate, not flat per-compound pricing.

The PlexusDx Precision Peptide Genetic Test ($298) analyzes GIPR, FTO, and MC4R — variants that relate to GLP-1 and related signaling pathways. It does not predict your response to tirzepatide or determine your dose; it offers pathway-level context for a conversation with your provider. Genetics is a guide, not a guarantee.

Common Side Effects and How They Compare

Both tirzepatide and semaglutide can cause nausea, vomiting, diarrhea, or constipation as your digestive system adjusts to slower stomach emptying. These effects typically peak during the first 2–4 weeks and subside as your body adapts. Tirzepatide side effects are generally similar in type to semaglutide but may occur more frequently or intensely because of the dual-receptor activation. Patients on tirzepatide occasionally report greater appetite suppression, which some experience as difficulty eating enough protein.

Rare but serious risks include pancreatitis, gallbladder problems, and thyroid changes—concerns that apply to both medications. Neither compound is appropriate for people with personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2. Starting at the lowest effective dose and increasing gradually reduces side-effect burden. PlexusDx providers monitor your symptoms at each visit and adjust your medication or dose if needed.

How Your Genetics Relate to GLP-1 Pathways

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, FTO rs9939609, and MC4R rs17782313 — relate to the biological pathways these medications act on. These are pathway-level associations only and do not predict how much weight you will lose or how you will respond to any specific medication. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights so you and your provider can see how your genes relate to these pathways. It does not recommend, prescribe, or determine which medication, dose, or peptide is right for you. The PlexusDx Precision Peptide Genetic Test ($298) gives you and your provider pathway-level genetic context to support a more personalized conversation. Genetics is a guide, not a guarantee.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers seven prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Injection is $289/mo month-to-month, or from $249/mo on the 6-month plan. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $298 to personalize your protocol from day one.

Frequently Asked Questions

Should I start with semaglutide or tirzepatide?

If you have modest weight to lose (20–50 pounds) and no prediabetes, semaglutide is a proven, cost-effective starting point. If you need to lose more than 50 pounds, have prediabetes or metabolic syndrome, or have tried semaglutide without sufficient results, tirzepatide's dual-action mechanism often produces faster, larger weight loss. The Precision Peptide Genetic Test can confirm which medication aligns with your genetic predispositions.

How much weight loss can I expect with tirzepatide?

Clinical trials show average weight loss of 20–22% of body weight over 72 weeks with tirzepatide, though individual results vary widely. Someone weighing 250 pounds might lose 50–55 pounds, while someone at 180 pounds might lose 36–40 pounds. Weight loss typically accelerates during months 2–6, then slows as your body adapts; most patients achieve their maximum loss by month 12.

How much does compounded tirzepatide cost at PlexusDx?

PlexusDx tirzepatide injections are $289/mo month-to-month, or from $249/mo on the 6-month plan with no flat per-compound pricing increases. Your dose may need to go up as treatment progresses, but your monthly price remains flat. All medications are compounded in licensed 503A pharmacies, require no insurance, and are available in all 50 states.

Are compounded semaglutide and tirzepatide safe?

Yes—PlexusDx sources all medications from licensed 503A compounding pharmacies that follow FDA sterility and potency standards. However, compounded medications are not FDA-approved in the same way brand-name Wegovy, Zepbound, or Mounjaro are. You should discuss the benefits and risks with your PlexusDx provider, especially if you have thyroid disease, pancreatitis history, or severe kidney problems.

What does the Precision Peptide Genetic Test reveal?

No — the Precision Peptide Genetic Test does not predict your response to tirzepatide or any specific medication. It analyzes pathway-level variants (GIPR (rs1800437), FTO, and MC4R) that relate to the biology involved, offering context for a conversation with your provider rather than a prediction.

Related Reading

• Wegovy Vs Zepbound Weight Loss
• Wegovy For Weight Loss 2
• Wegovy Weight Loss Pills
• Zepbound For Weight Loss

Pricing and availability current as of June 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.

Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.